Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Osteosarcoma 2Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Pathologic Complete Response 1Neoplasms 1Hemangiosarcoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 25Temozolomide 22Vincristine 18Irinotecan 18Doxorubicin 13Topotecan 10Melphalan 10Etoposide 10Ifosfamide 8Busulfan 8cabozantinib 7Magnetic Resonance Spectroscopy 7Granulocyte Colony-Stimulating Factor 7Filgrastim 6regorafenib 5fludarabine 5X-Rays 5Specimen Handling 5Sirolimus 5Radiotherapy 5Gemcitabine 5Drug Therapy 5pegfilgrastim 4palbociclib 4liposomal doxorubicin 4irinotecan sucrosofate 4ganitumab 4fludarabine phosphate 4Trabectedin 4Phantoms, Imaging 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Ewing × trilaciclib × Sarcoma × Clear all
NCT06699472 2024-11-21

A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib

Fudan University

Phase 2 Recruiting
22 enrolled
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡